ArticleApplied and environmental microbiology2025
Approaches for inactivating highly pathogenic avian influenza H5N1 cattle isolate for safe containment level 2 laboratory practices.
Article in Applied and environmental microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Standing HA phenotypic breadth shapes H5N1 cross-host potential.Research square · 2026Article
- Evaluation of beta-propiolactone and AVL-ethanol inactivation protocols for highly pathogenic avian influenza virus in allantoic fluid and cell culture.Applied and environmental microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In March 2024, highly pathogenic avian influenza (HPAI) H5N1 was detected in Texas dairy cattle and has since spread to over 500 herds in the United States. Historically, H5N1 transmission to humans has occurred because of contact with infected birds, and over 800 cases have been reported since 2003, with a mortality rate of 52%. Sustained human-to-human transmission of H5N1 has not been observed. HPAI requires physical containment and operational practices to be completed in a containment level 3 (CL-3) laboratory. To safely bring samples containing inactivated HPAI to CL-2 laboratories for further analysis, we tested methods of inactivation for downstream RNA extraction or antibody response assays. Samples containing A/dairy cattle/Texas/24-008749-002/2024 (H5N1 cattle virus) destined for RNA extraction were incubated with Buffer AVL (Qiagen) with 95% ethanol, or Buffer RLT (Qiagen) with 70% ethanol. Samples tested for antibody assays, serum, and milk containing HPAI were incubated with 0.5% vol/vol Triton X-100 at 60°C. We found that Buffer AVL with 95% ethanol inactivated H5N1 cattle virus in supernatant from infected cells, milk, blood, and urine. Buffer RLT with 70% ethanol inactivated H5N1 cattle virus in infected cell pellet, spiked milk, blood, urine, and tissue. Finally, incubation with 0.5% vol/vol Triton X-100 followed by a 30 minute heat treatment at 60°C completely inactivated the H5N1 cattle virus in whey and serum. This work is essential for allowing the safe transfer of H5N1 samples produced in CL-3 to lower containment laboratories for downstream analyses.IMPORTANCEHistorically, human infections from highly pathogenic avian influenza (HPAI) have occurred from contact with infected birds, with estimated mortality rates of 52%. Recently, this virus has spilled over into many mammalian species and has rapidly spread between dairy cattle herds in the United States, causing multiple human infections after exposure to infected cows. Characterization of this virus is imperative for reducing risk to humans. Work with live HPAI virus must be undertaken in containment level 3 facilities, which limits the amount and type of work that can be done due to time-consuming biosafety procedures and lack of equipment. In this article, we outline how to effectively inactivate HPAI to enable safe work in containment level 2 facilities and facilitate more efficient work on this pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.